KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Takeda Pharmaceutical (TAK) Tax Provisions (2017 - 2025)

Historic Tax Provisions for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to -$195.8 million.

  • Takeda Pharmaceutical's Tax Provisions rose 3342.24% to -$195.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.6 billion, marking a year-over-year increase of 729.82%. This contributed to the annual value of $439.5 million for FY2025, which is 16933.47% up from last year.
  • Takeda Pharmaceutical's Tax Provisions amounted to -$195.8 million in Q4 2025, which was up 3342.24% from -$1.4 billion recorded in Q3 2025.
  • Over the past 5 years, Takeda Pharmaceutical's Tax Provisions peaked at $390.1 million during Q2 2022, and registered a low of -$1.4 billion during Q3 2025.
  • Its 5-year average for Tax Provisions is -$402.9 million, with a median of -$318.2 million in 2024.
  • As far as peak fluctuations go, Takeda Pharmaceutical's Tax Provisions skyrocketed by 16715.4% in 2022, and later crashed by 98636.55% in 2023.
  • Takeda Pharmaceutical's Tax Provisions (Quarter) stood at -$126.4 million in 2021, then surged by 167.15% to $84.9 million in 2022, then plummeted by 503.15% to -$342.3 million in 2023, then increased by 14.11% to -$294.0 million in 2024, then skyrocketed by 33.42% to -$195.8 million in 2025.
  • Its Tax Provisions stands at -$195.8 million for Q4 2025, versus -$1.4 billion for Q3 2025 and -$575.7 million for Q2 2025.